SUTENT® is indicated for the treatment of advanced/metastatic renal cell carcinoma (mRCC) in adults. Ref 1
Metastatic renal cell carcinoma (mRCC)
Support & Services
Clinical Efficacy
Real-World Experience
Patient Support
Prescribing Information
1. SUTENT® Summary of Product Characteristics. Pfizer. Available at: www.medicines.ie
Accessed August 2019. PP-SUT-IRL-0120. August 2019.
